|
Synonyms: JNJ-64407564 | JNJ64407564 | talquetamab-tgvs | Talvey®
talquetamab is an approved drug (FDA & EMA (2023))
Compound class:
Antibody
Comment: Talquetamab (JNJ-64407564) is a humanized, IgG4 bispecific monoclonal antibody that engages the orphan GPCR GPRC5D that's expressed on majority of malignant plasma cells from multiple myeloma (MM) patients and CD3ε on T cells [3]. It has amino acid substitutions in its Fc region to minimise binding to Fcγ receptors and antibody-directed effector functions. The peptide sequences for talquetamab's heavy and light chains are claimed in Janssen's patent US10562968B2 [1]. In preclinical studies talquetamab promoted immune killing of MM cells, including cells from patients with daratumumab-refractory disease [4].
|
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (FDA & EMA (2023)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 11173 | talquetamab |
| Synonyms |
| JNJ-64407564 | JNJ64407564 | talquetamab-tgvs | Talvey® |
| Database Links |
|
| Specialist databases | |
| GPCRdb Ligand | talquetamab |
| IMGT/mAb-DB | 973 |
| Other databases | |
| GtoPdb PubChem SID | 473153828 |
| Search PubMed clinical trials | talquetamab |
| Search PubMed titles | talquetamab |
| Search PubMed titles/abstracts | talquetamab |
